- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Amgen Inc(AMGN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AMGN
11/13/2026: AMGN (5-star) is a STRONG-BUY. BUY for 20 days. Simulated Profits (9.58%). Updated daily EoD!
Amgen Inc is a major global biotechnology company specializing in innovative human therapeutics for oncology, cardiovascular disease, inflammation, and rare diseases. The company's key business strengths include robust biologics manufacturing expertise, high operating margins, and strong cash generation from leading products like Repatha and Tezspire. Its primary growth opportunity centers on expanding its rare disease portfolio and advancing promising late-stage pipeline assets such as obesity candidate MariTide. However, key risks include heavy debt from recent acquisitions and accelerating revenue erosion from biosimilar competition facing legacy blockbusters like Prolia. The stock suits dividend and value-oriented investors seeking stable cash flows, while requiring monitoring of patent cliffs and clinical trial progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Amgen offers steady mid-single-digit revenue expansion and exciting pipeline catalysts, but lacks hyper-growth characteristics. |
| Momentum investor | Strong fit while signal remains positive | Momentum fit depends on favorable near-term clinical readouts and positive technical price trends. |
| Value investor | Mixed fit | Reasonable valuation multiples are balanced by high debt levels and patent expiration risks. |
| Dividend investor | Strong fit | Amgen provides a solid dividend yield backed by resilient free cash flow and a history of payout growth. |
| Low-risk investor | Medium | While established and cash-generative, biopharmaceutical regulatory and pipeline execution risks introduce moderate volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | Biotech shares can fluctuate based on clinical trial outcomes, regulatory decisions, and broader market conditions. |
| Valuation risk | Medium | Valuation depends heavily on successful pipeline delivery to offset legacy patent cliffs. |
| Competition risk | High | Intense competition from major biopharma peers and biosimilar manufacturers threatens market share. |
| Business quality | Strong | Amgen possesses a high-quality franchise with leading biologics manufacturing expertise and robust operating margins. |
| Dividend income | Low | Dividend payouts are well-supported by robust and predictable free cash flow generation. |
| Execution risk | Medium / high | Successful integration of acquired assets and delivery of late-stage pipeline candidates are critical for long-term growth. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 251.89B USD | Price to earnings Ratio 27 | 1Y Target Price 431.81 |
Price to earnings Ratio 27 | 1Y Target Price 431.81 | ||
Volume (30-day avg) 2.7M shares | Beta 0.42 | 52 Weeks Range 306.13 - 483.99 | Updated Date 11/15/2026 |
52 Weeks Range 306.13 - 483.99 | Updated Date 11/15/2026 | ||
Dividends yield (FY) 2.13% | Basic EPS (TTM) 17.25 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - General
- BUY participation
- 77.8%
- Active BUY / eligible
- 7 / 9
- 30-Day BUY Count Change
- +4
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 61.43% | Avg. Invested days 53 | Today’s Advisory Strong Buy |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| General Medicine & Bone Health | Includes key products like Prolia, Xgeva, and Evenity targeting osteoporosis and bone density disorders. | These products form a major revenue foundation, though they face near-term generic erosion. |
| Cardiovascular & Inflammation | Includes blockbuster therapies such as Repatha for cholesterol and Otezla for psoriasis. | Repatha acts as a powerful volume growth engine offsetting declines in older franchises. |
| Rare Diseases | Specialized medicines acquired via Horizon Therapeutics, including Tepezza and Krystexxa. | Adds high-margin, specialized revenue streams diversifying the core portfolio. |
| Oncology & Biosimilars | Includes oncology products like Blincyto and Kyprolis, alongside a growing portfolio of biosimilar drugs. | Provides balanced exposure to cancer treatments and cost-effective alternatives to expensive biologics. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-03 | When After Market | Estimate 5.74 | Actual 6.45 |
Profitability
Profit Margin 24.14% | Operating Margin (TTM) 34.12% |
Management Effectiveness
Return on Assets (TTM) 8.91% | Return on Equity (TTM) 78.35% |
Valuation
Trailing PE 27 | Forward PE 19.05 | Enterprise Value 292.70B | Price to Sales(TTM) 6.47 |
Enterprise Value 292.70B | Price to Sales(TTM) 6.47 | ||
Enterprise Value to Revenue 7.52 | Enterprise Value to EBITDA 16.11 | Shares Outstanding 540.91M | Shares Floating 539.44M |
Shares Outstanding 540.91M | Shares Floating 539.44M | ||
Percent Insiders 0.57 | Percent Institutions 84.89 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

